NFKB1 and hepatocellular carcinoma: Another in vivo study evaluated the effect of the NF-κB inhibitor nafamostat mesylate alone or in combination with adenoviral vector-expressing tumor necrosis factor (TNF)-α in an HCC xenograft model.